BMO analyst maintains Outperform on Novo Nordisk but voices ...
BMO analyst maintains Outperform on Novo Nordisk but voices concerns about market challenges and new offerings. Regulatory hurdles for Medicare coverage under Trump administration may impact GLP-1 usage for heart disease and sleep apnea.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more